Although HER2+ breast cancers grow quicker and are more invasive than other types, thanks to applying the antibodies directed against HER2 receptors, they are generally approachable to anti-HER2 therapy, which significantly enhances the prognosis [163,169]. This evidence concerns the gene ERBB2 and breast cancer.